Journal ArticleDOI
A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis
Joan M. Bathon,Richard J. Martin,Roy Fleischmann,John Tesser,Michael Schiff,Edward C. Keystone,Mark C. Genovese,Mary Chester M. Wasko,Larry W. Moreland,Arthur L. Weaver,Joseph A. Markenson,Barbara K. Finck +11 more
TLDR
Subcutaneous [corrected] etanercept acted more rapidly to decrease symptoms and slow joint damage in patients with early active rheumatoid arthritis.Abstract:
Background Etanercept, which blocks the action of tumor necrosis factor, reduces disease activity in patients with long-standing rheumatoid arthritis. Its efficacy in reducing disease activity and preventing joint damage in patients with active early rheumatoid arthritis is unknown. Methods We treated 632 patients with early rheumatoid arthritis with either twice-weekly subcutaneous etanercept (10 or 25 mg) or weekly oral methotrexate (mean, 19 mg per week) for 12 months. Clinical response was defined as the percent improvement in disease activity according to the criteria of the American College of Rheumatology. Bone erosion and joint-space narrowing were measured radiographically and scored with use of the Sharp scale. On this scale, an increase of 1 point represents one new erosion or minimal narrowing. Results As compared with patients who received methotrexate, patients who received the 25-mg dose of etanercept had a more rapid rate of improvement, with significantly more patients having 20 percent, ...read more
Citations
More filters
Journal ArticleDOI
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
Josef S Smolen,Robert Landewé,Ferdinand C. Breedveld,Maya H Buch,Maya H Buch,Gerd R Burmester,Maxime Dougados,Paul Emery,Paul Emery,Cécile Gaujoux-Viala,Laure Gossec,Jackie L Nam,Jackie L Nam,Sofia Ramiro,Kevin L. Winthrop,Maarten de Wit,Daniel Aletaha,Neil Betteridge,Johannes W. J. Bijlsma,Maarten Boers,Frank Buttgereit,Bernard Combe,Maurizio Cutolo,Nemanja Damjanov,Johanna M. W. Hazes,Marios Kouloumas,Tore K Kvien,Xavier Mariette,Karel Pavelka,Piet L. C. M. van Riel,Andrea Rubbert-Roth,Marieke Scholte-Voshaar,David Scott,T. Sokka-Isler,John B. Wong,Désirée van der Heijde +35 more
TL;DR: These recommendations intend informing rheumatologists, patients, national rheumology societies, hospital officials, social security agencies and regulators about EULAR's most recent consensus on the management of RA, aimed at attaining best outcomes with current therapies.
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
Josef S Smolen,Robert Landewé,Ferdinand C. Breedveld,Maxime Dougados,Paul Emery,Cécile Gaujoux-Viala,Simone L Gorter,Rachel Knevel,Jackie L Nam,Monika Schoels,Daniel Aletaha,Maya H Buch,Laure Gossec,T.W.J. Huizinga,Johannes W. J. Bijlsma,G.-R. Burmester,B. Combe,Maurizio Cutolo,Cem Gabay,Juan J. Gomez-Reino,Marios Kouloumas,Tore K Kvien,E. Martin-Mola,Iain B. McInnes,Karel Pavelka,P.L.C.M. van Riel,M. Scholte,David Scott,T. Sokka,Guido Valesini,R. van Vollenhoven,Kevin L. Winthrop,John B. Wong,A. Zink,D. van der Heijde +34 more
TL;DR: Recommendations are intended to inform rheumatologists, patients and other stakeholders about a European consensus on the management of RA with DMARDs and GCs as well as strategies to reach optimal outcomes of RA based on evidence and expert opinion.
Journal ArticleDOI
Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial
Lars Klareskog,Désirée van der Heijde,Julien P de Jager,A. K. S. Gough,Joachim R. Kalden,Michel Malaise,Emilio Martin Mola,Karel Pavelka,Jacques Sany,L. Settas,Joseph Wajdula,Ronald Pedersen,Saeed Fatenejad,Marie Sanda +13 more
TL;DR: The combination of etanercept and methotrexate was significantly better in reduction of disease activity, improvement of functional disability, and retardation of radiographic progression compared with methotRexate or etanorcept alone.
Journal ArticleDOI
The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment
Ferdinand C. Breedveld,Michael H. Weisman,Arthur Kavanaugh,Stanley Cohen,Karel Pavelka,Ronald F van Vollenhoven,John T. Sharp,John L. Perez,George Spencer-Green +8 more
TL;DR: Combination therapy with adalimumab plus MTX was significantly superior to either MTX alone or ad alimumab alone in improving signs and symptoms of disease, inhibiting radiographic progression, and effecting clinical remission in patients with early, aggressive rheumatoid arthritis.
Journal ArticleDOI
Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
TL;DR: The biology of T NF and related family members are discussed in the context of the potential mechanisms of action of TNF antagonists in a variety of immune-mediated inflammatory diseases.
References
More filters
Journal ArticleDOI
American college of rheumatology preliminary definition of improvement in rheumatoid arthritis
David T. Felson,David T. Felson,Jennifer J. Anderson,Jennifer J. Anderson,Maarten Boers,Claire Bombardier,Claire Bombardier,Daniel E. Furst,Daniel E. Furst,Charles H. Goldsmith,Charles H. Goldsmith,Linda M. Katz,Linda M. Katz,Robert W. Lightfoot,Robert W. Lightfoot,Harold E. Paulus,Harold E. Paulus,Vibeke Strand,Vibeke Strand,Peter Tugwell,Peter Tugwell,Michael E. Weinblatt,Michael E. Weinblatt,H. James Williams,H. James Williams,Frederick Wolfe,Stephanie Kieszak +26 more
TL;DR: The results suggest that the definition of improvement presented is statistically powerful and does not identify a large percentage of placebo-treated patients as being improved, which the authors hope will be used widely in RA trials.
Journal ArticleDOI
A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.
Michael E. Weinblatt,Joel M. Kremer,Arthur D. Bankhurst,Ken J. Bulpitt,Roy Fleischmann,Robert I. Fox,Christopher G. Jackson,Mary Lange,Daniel Burge +8 more
TL;DR: In patients with persistently active rheumatoid arthritis, the combination of etanercept and methotrexate was safe and well tolerated and provided significantly greater clinical benefit than metotrexate alone.
Journal ArticleDOI
Cancer statistics, 1997
Journal ArticleDOI
Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein.
Larry W. Moreland,Scott Baumgartner,Michael Schiff,Elizabeth A. Tindall,Roy Fleischmann,Arthur L. Weaver,Robert E. Ettlinger,Stanley Cohen,William J. Koopman,Kendall Mohler,Michael B. Widmer,Consuelo M. Blosch +11 more
TL;DR: In this three-month trial TNFR:Fc was safe, well tolerated, and associated with improvement in the inflammatory symptoms of rheumatoid arthritis.
Journal ArticleDOI
Etanercept Therapy in Rheumatoid Arthritis: A Randomized, Controlled Trial
Larry W. Moreland,Michael Schiff,Scott Baumgartner,Elizabeth A. Tindall,Roy Fleischmann,Ken J. Bulpitt,Arthur L. Weaver,Edward C. Keystone,Daniel E. Furst,Philip J. Mease,Eric Ruderman,David A. Horwitz,Daniel G. Arkfeld,Leslie Garrison,Daniel Burge,Consuelo M. Blosch,Mary Lange,Neil D. McDonnell,Michael E. Weinblatt +18 more
TL;DR: In a phase II study, etanercept (recombinant human tumor necrosis factor receptor [p75]:Fc fusion protein) safely produced rapid, dose-dependent improvement in rheumatoid arthritis over 3 months as discussed by the authors.